Question explored with the scientific record
Conversation so far
- 1 Do statins reduce strokes?
- 2 What benefits do statins show for people without heart disease (primary prevention)?
- 3 What about ezitimibe for cardiovascular disease and stroke prevention
- 4 What are the main safety risks of ezetimibe+statin (e.g., cancer)?
- 5 What about ezetimibe without statin? Is it an effective therapy?
- 6 How much LDL lowering and heart-risk reduction does ezetimibe monotherapy achieve?
Answered on this page ↓
How much LDL lowering and heart-risk reduction does ezetimibe monotherapy achieve?
The short version: ezetimibe monotherapy lowers LDL by roughly 12–18%, but no trial here shows that translates into fewer heart attacks or strokes.
The best monotherapy numbers come from a 2003 study of 892 patients, which found LDL dropped about 17.7% [1]. A 2003 review put the range at 12–18% [3]. A 2008 clinical-practice study reported a larger 31.4% LDL drop, but that mixed monotherapy and combination patients, so it overstates what ezetimibe alone does [2].
The cardiovascular question is where the evidence collapses. Every major outcome trial in this retrieval added ezetimibe to a statin. The 2024 meta-analysis of 106,358 people found statin-plus-ezetimibe cut major cardiovascular events by about 28% versus statin alone [5]. A 2025 diabetes cohort found a 33% relative reduction in major events [4]. But those are combination results. No retrieved study tested ezetimibe alone against placebo for heart attacks or death.
The 2024 review of statin add-ons is blunt: ezetimibe reduced composite cardiovascular endpoints but did not significantly reduce cardiovascular death [6]. That is the best outcome data available, and it applies to ezetimibe on top of a statin, not ezetimibe alone.
| Measure | Ezetimibe monotherapy | Statin + ezetimibe |
|---|---|---|
| LDL reduction | ~12–18% [1][3] | ~25% added on top of statin [1] |
| Cardiovascular death reduction | No trial data | Not significant [6] |
| Major event reduction | No trial data | ~28% relative [5] |
My call: ezetimibe alone is a modest LDL-lowering drug with no proven effect on heart attacks, strokes, or death. The benefit shown in trials belongs to the statin combination. Confidence: low for monotherapy benefit, moderate for the LDL-lowering number.
Sources used 6
-
Ezetimibe: a novel option for lowering cholesterol
This study evaluates the efficacy and safety of ezetimibe, a cholesterol absorption inhibitor, in lowering LDL-cholesterol levels in patients with hypercholesterolemia, both as monotherapy and in combination with statins.
DOI: 10.1586/14779072.1.1.11 -
Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study
The SI-SPECT study evaluated the effectiveness of ezetimibe, both as monotherapy and in combination with statins, in lowering lipid levels in dyslipidaemic patients in Slovenia, demonstrating significant reductions in total cholesterol, LDL cholesterol, and triglycerides over a …
DOI: 10.1185/03007990802303772 -
Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials
This Expert Opinion review summarizes ezetimibe’s mechanism as a Niemann–Pick C1-like 1 (NPC1L1) cholesterol absorption inhibitor, its pharmacokinetics and drug interactions, and clinical trial evidence for LDL-C lowering alone and in combination with statins and other agents, a…
DOI: 10.1517/17425255.3.3.441 -
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482 -
The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.
This meta-analysis compares upfront lipid-lowering therapy combining statins with ezetimibe versus statin monotherapy, showing greater LDL-C reduction and improved cardiovascular outcomes with similar safety profiles across 11 studies comprising 106,358 participants.
DOI: 10.1093/eurheartj/ehae666.2873 -
Effect of statin add-on therapy on cardiovascular mortality
This narrative review of cardiovascular outcomes trials for statin add-on therapies found that only icosapent ethyl significantly reduced cardiovascular mortality, while ezetimibe, PCSK9 inhibitors, and bempedoic acid reduced composite CV endpoints but not CV mortality.
DOI: 10.3389/fcvm.2024.1308695